Aylin Domaniku Waraich

Skilled researcher with a strong background in academic collaboration and a proven track record in conducting high-level research initiatives. Expertise in cancer biology, cytokine signaling, and translational research. Currently leading scientific design and development of interactive digital biology modules at an R&D Center. Seeking a Postdoc position in academia to apply molecular insights to disease mechanisms and drive therapeutic innovation. Particularly interested in ageing, cardiovascular & metabolic diseases.

• Academic Excellence Award – Koç University (2024)
• Golden Brain Valedictorian Award – Bahçeşehir University (2019)

• Agca, S., Waraich, A.D., Bilgic, S.N., Sucuoglu, M., Dag, M., Dogan, S.A., Kir, S. (2024). Tumor-induced alterations in single-nucleus transcriptome of atrophying muscles indicate enhanced protein degradation and reduced oxidative metabolism. Journal of Cachexia, Sarcopenia & Muscle. DOI: 10.1002/jcsm.13540
• Domaniku-Waraich, A., Agca, S., Toledo, B., Sucuoglu, M., Özen, S.D., Bilgic, S.N., Arabaci, D.H., Kashgari, A.E., Kir, S. (2024). Oncostatin M signaling drives cancer-associated skeletal muscle wasting. Cell Reports Medicine, 5(4), 101498. DOI: 10.1016/j.xcrm.2024
• Domaniku, A., Bilgic, S.N., Kir, S. (2023). Muscle wasting: emerging pathways and potential drug targets. Trends in Pharmacological Sciences, 44, 705-718.
• Bilgic, S.N., Domaniku, A., Toledo, B., Agca, S., Weber, B.Z.C., Arabaci, D.H., Ozornek, Z., Lause, P., Thissen, J.P., Loumaye, A., Kir, S. (2023). EDA2R-NIK signaling promotes muscle atrophy linked to cancer cachexia. Nature, 617, 827-834. Commented by: Antonio-Herrera, L., Bergthaler, A. (2023). Molecular basis for muscle loss that causes cachexia. Nature, 617, 684-685. The EDA2R-NIK Axis Promotes Muscle Atrophy and Cancer Cachexia. Cancer Discovery (2023). DOI: 10.1158/2159-8290.CD-RW2023-079
• Weber, B.Z.C., Agca, S., Domaniku, A., Bilgic, S.N., Arabaci, D.H., Kir, S. (2022). Inhibition of epidermal growth factor receptor suppresses tumor parathyroid hormone-related protein expression and ameliorates cancer-associated cachexia. Journal of Cachexia, Sarcopenia & Muscle, 3, 1582-1594.
• Månberg, A., Skene, N., Sanders, F., Trusohamn, M., Remnestål, J., Szczepiñska, A., Aksoylu, I.S., Lönnerberg, P., Ebarasi, L., Wouters, S., Lehmann, M., Olofsson, J., von Gohrén Antequera, I., Domaniku, A., De Schaepdryver, M., De Vocht, J., Poesen, K., Uhlén, M., Anink, J., Mijnsbergen, C., Vergunst-Bosch, H., Hübers, A., Kläppe, U., Rodrigue-Veitez, E., Gilthorpe, J.D., Hedlund, E., Harris, R.A., Aronica, E., Van Damme, P., Ludolph, A., Veldink, J., Ingre, C., Nilsson, P., Lewandowski, S.A. (2021). Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 27, 640-646. DOI: 10.1038/s41591-021-01295-9
• Kandemiş, E., Domaniku, A., Polat, İ., Bulut, G. (2018). Effect of Gemcitabine on HOTAIR Expression Level in H596 and H1944 Cell Lines. Proceedings 2018, 2, 1590. DOI: 10.3390/proceedings2251590

• TÜBİTAK - PhD Scholarship (2019–2024)
• Amgen Scholar – Karolinska Institutet (2018)
• BİTAK - Undergraduate Assistantship (2018–2019)
• Bahçeşehir University Full Scholarship (2015–2019)